Clinical trials: 5-FU
Neoplasms
A Study of Encorafenib Plus Cetuximab With or Without Chemotherapy in People With Previously Untreated Metastatic Colorectal Cancer
The purpose of this study is to evaluate two study medicines (encorafenib plus cetuximab) taken alone or together with standard chemotherapy for the potential treatment of colorectal cancer that: has spread to other parts of the…
- Trial name
- NCT04607421
- Testing
- Encorafenib, Cetuximab, Oxaliplatin
- Where
- 272 sites in United States, Argentina and 27 more
- Volunteers
- 841 people
- Sponsor
- Pfizer
mCRC
A Phase I Multicentre Randomized Double-Blind Parallel-Controlled Study of HLX05-N vs. ERBITUX® in Metastatic Colorectal Cancer
This is a multicentre, randomized, double-blind, parallel-controlled Phase 1 clinical study designed to evaluate the pharmacokinetic (PK) similarity, efficacy, safety, and immunogenicity of HLX05-N compared with US-sourced…
- Trial name
- PK similarity (NCT07543471)
- Testing
- Cetuximab, mFOLFOX6
- Volunteers
- 387 people
- Sponsor
- Shanghai Henlius Biotech
Bilateral Vocal Cord Paralysis
Performance of the SPIRION Laryngeal Pacemaker in BVFP Patients With Single-sided Glottal Enlargement
The goal of this clinical investigation is to learn about the use of a novel medical device, the SPIRION Laryngeal Pacemaker, in patients suffering from bilateral vocal fold paralysis (BVFP) and who have had at least one related…
- Trial name
- NCT06007144
- Testing
- SPIRION Laryngeal Pacemaker System Implantation and follow-up
- Where
- 6 sites in Austria, Germany
- Volunteers
- 10 people
- Sponsor
- MED-EL Elektromedizinische Geräte GmbH
Metastatic Colorectal Cancer
Study of CS-1008 in Combination With FOLFIRI in Patients Who Have Failed Other Treatments
Treatment with CS-1008 in combination with FOLFIRI (irinotecan, leucovorin, and 5-fluorouracil [5-FU]) in subjects with metastatic colorectal cancer (CRC) who have failed first-line treatment that was not irinotecan-based.
- Trial name
- NCT01124630
- Testing
- CS-1008, FOLFIRI
- Where
- 3 sites in United States
- Volunteers
- 21 people
- Sponsor
- Daiichi Sankyo
Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma
A Study of Pembrolizumab (MK-3475) in Participants With Recurrent or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma (MK-3475-059/KEYNOTE-059)
This is a study of pembrolizumab (MK-3475) for advanced gastric or gastroesophageal junction adenocarcinoma; pembrolizumab will be given as monotherapy to participants who have had previous treatment or who are treatment-naïve…
- Trial name
- NCT02335411
- Testing
- pembrolizumab, cisplatin, 5-FU
- Volunteers
- 318 people
- Sponsor
- Merck Sharp & Dohme LLC
Pancreatic Cancer
A Study of TNFerade™ Biologic With 5-FU and Radiation Therapy for First-Line Treatment of Unresectable Locally Advanced Pancreatic Cancer
The primary purpose of this study is to assess the safety and effectiveness of TNFerade™ Biologic when administered concurrently with 5-FU and radiation therapy as first-line treatment of unresectable locally advanced pancreatic…
- Trial name
- NCT00051467
- Testing
- TNFerade
- Where
- 25 sites in United States
- Sponsor
- GenVec
Oncology
Rollover Study to Provide Continued Access to Napabucasin for Patients Enrolled in Boston Biomedical-sponsored Protocols
This is an open-label, multi-center, multi-national, non-randomized rollover study designed to allow continued access to napabucasin for patients who have participated in a Boston Biomedical-sponsored study and are being treated…
- Trial name
- NCT04299880
- Testing
- Napabucasin, Nab-paclitaxel, Gemcitabine
- Where
- 7 sites in United States, France and 2 more
- Volunteers
- 7 people
- Sponsor
- Sumitomo Pharma America, Inc.
Toxicity Due to Chemotherapy
Uridine Triacetate as Antidote for Patients at Excess Risk of 5-FU Toxicity Due to Overdosage or Impaired Elimination
The purpose of this study is to provide emergency treatment of adult and pediatric patients: Following a fluorouracil or capecitabine overdose regardless of the presence of symptoms or Who exhibit early-onset, severe or…
- Trial name
- NCT01432301
- Testing
- uridine triacetate
- Sponsor
- Wellstat Therapeutics
Uterine Neoplasms
Patients Who Have Failed First Line Treatment for Locally Advanced and/or Metastatic Cervical Cancer
Primary: To assess the overall response rate of oxaliplatin in patients with bidimensionally measurable disease at baseline. Secondary: To assess the safety and tolerability of oxaliplatin To assess time to progression and…
- Trial name
- NCT00782041
- Testing
- Oxaliplatin, 5-FluoroUracil, Folinic acid
- Where
- Thailand
- Volunteers
- 11 people
- Sponsor
- Sanofi
Colorectal Cancer Metastatic, mCRC
QUILT 3.071: NANT Colorectal Cancer (CRC) Vaccine
QUILT 3.071 NANT Colorectal Cancer (CRC) Vaccine: This is a Phase 1b/2 study investigating the effect of NANT CRC vaccine vs regorafenib in subjects with CRC who were previously treated with SOC.
- Trial name
- NCT03563157
- Testing
- Aldoxorubicin Hydrochloride, ALT-803, ETBX-011
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- ImmunityBio, Inc.
Gastric Cancer
Novel Combinations in Participants With Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma
This is a Phase II, open-label, multi-drug, multi-centre study designed to assess the efficacy, safety, tolerability, pharmacokinetics, and immunogenicity of novel combination therapies in participants with locally advanced…
- Trial name
- NCT05702229
- Testing
- Rilvegostomig, Volrustomig, FOLFOX
- Where
- 44 sites in United States, China and 5 more
- Volunteers
- 163 people
- Sponsor
- AstraZeneca
Colorectal Cancer
A Study Comparing the Efficacy and Safety of Vanucizumab and FOLFOX With Bevacizumab and FOLFOX in Participants With Untreated Metastatic Colorectal Cancer
This is a Phase 2 multicenter, randomized, parallel arms, double-blind study of vanucizumab to evaluate the efficacy and safety of vanucizumab in combination with oxaliplatin, folinic acid, and 5-fluorouracil (5-FU) (mFOLFOX-6)…
- Trial name
- McCAVE (NCT02141295)
- Testing
- 5-FU, Bevacizumab, Folinic acid
- Where
- 39 sites in United States, Australia and 5 more
- Volunteers
- 197 people
- Sponsor
- Hoffmann-La Roche
Metastatic Colorectal Cancer (CRC)
ARTEMIS-102: HS-20093 Combinations in Patients with Advanced Metastatic Colorectal Cancer
HS-20093 is a fully humanized IgG1 antibody-drug conjugate (ADC) which specifically binds to B7-H3, a target wildly expressed on solid tumor cells.
- Trial name
- NCT06825624
- Testing
- HS-20093, Bevacizumab, 5-FU
- Where
- China
- Volunteers
- 560 people
- Sponsor
- Hansoh BioMedical R&D Company
Advanced Colorectal Cancer
A Study of AL2846 Capsule Combined With Standard Chemotherapy Regimen in Subjects With Advanced Colorectal Cancer
This is a study to explore the safety, tolerance and efficacy of AL2846 capsules combined with mFOLFOLX6 or FOLFIRI standard chemotherapy regimen in subjects with advanced metastatic colorectal cancer.
- Trial name
- NCT04337879
- Testing
- AL2846, Calcium folate, 5-FU
- Where
- China
- Volunteers
- 56 people
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Head and Neck Neoplasms
Docetaxel in Head and Neck Cancer
Primary Objective: Phase II: To determine the best treatment scheme (TPF vs. PF). Phase III: To compare the time to progression and the treatment failure at the 3 arms. Secondary objectives: To evaluate the safety at the 3 arms.
- Trial name
- NCT00261703
- Testing
- Docetaxel, Cisplatin, 5-fluorouracil (5-FU), radiotherapy, Cisplatin, 5-fluorouracil (5-FU), radiotherapy, Cisplatin + radiotherapy
- Where
- 2 sites in Portugal, Spain
- Volunteers
- 439 people
- Sponsor
- Sanofi
Neoadjuvant Therapy in Rectal Cancer
Preoperative Radiotherapy and E7046 in Rectum Cancer
This is a multicenter, open-label, Phase 1b study in participants with locally advanced rectum cancer where primary resection without chemoradiotherapy is unlikely to achieve clear margins as defined by magnetic resonance imaging…
- Trial name
- PRAER 1 (NCT03152370)
- Testing
- E7046, Long Course Chemoradiotherapy (LCRT), Short Course Radiotherapy (SCRT)
- Where
- 5 sites in United States, Poland and 1 more
- Volunteers
- 29 people
- Sponsor
- Adlai Nortye Biopharma Co., Ltd.
Vaginal Atrophy
Clinical Study of the CO2RE Laser Device Performance for Vaginal Atrophy Treatments
The CO2RE laser system is a fractional CO2 laser that is FDA approved under a 510(k) K101321 for dermatologic procedures requiring ablation and coagulation of soft tissues, including the skin Eligible subjects will undergo 3…
- Trial name
- NCT02704741
- Testing
- CO2RE
- Where
- 4 sites in United States
- Volunteers
- 61 people, healthy volunteers welcome
- Sponsor
- Syneron Medical
Stomach Neoplasms, Esophageal Neoplasms
Safety and Efficacy of G17DT Immunogen in the Treatment of Gastric and Gastroesophageal Cancer
This study will test whether the G17DT Immunogen, when administered in combination with chemotherapy, is an effective and safe treatment for gastric cancer.
- Trial name
- NCT00042510
- Testing
- Treatment group
- Volunteers
- 103 people
- Sponsor
- Cancer Advances Inc.
Advanced Malignant Tumors
A Phase Ib/II Study of AK112 in Combination With AK117 in Advanced Malignant Tumors
Phase Ib/II open label, multicenter study to evaluate the efficacy and safety of AK112 (anti-PD-1 and VEGF bispecific antibody) combined with AK117#AntiCD47 Antibody# in advanced malignant tumors
- Trial name
- NCT05229497
- Testing
- AK112, AK117, Carboplatin
- Where
- China
- Volunteers
- 154 people
- Sponsor
- Akeso
Breast Cancer
A Study of Pertuzumab in Combination With Herceptin and Chemotherapy in Participants With HER2-Positive Breast Cancer
This 3 arm study will assess the tolerability, safety and efficacy of 3 neoadjuvant treatment regimens in participants with locally advanced, inflammatory or early stage human epidermal growth factor receptor 2 (HER2)-positive…
- Trial name
- NCT00976989
- Testing
- Pertuzumab, Trastuzumab, FEC
- Where
- 55 sites in Bosnia and Herzegovina, Brazil and 18 more
- Volunteers
- 225 people
- Sponsor
- Hoffmann-La Roche